Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

The Association Between Adverse Childhood Experiences and Health-Related School Absenteeism: Results From a National Survey of Youth

Tsevat RK, Nkansah MM, Shankar M, Choi K, Jackson NJ, Thyne SM, Gordon B, Dudovitz RN. The Association Between Adverse Childhood Experiences and Health-Related School[...]

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui[...]

Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis, Fatigue, and Treatment With Avacopan: A Case Series

Schulze C. Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis, Fatigue, and Treatment With Avacopan: A Case Series. Cureus. 2025 Oct 20;17(10):e94987. doi: 10.7759/cureus.94987. PMID: 41280980; PMCID: PMC12631709.